Prolia (Denosumab) for Osteoporosis

Factors Associated with Low Bone Mass

• Demographic factors: Female sex, Caucasian or Asian ethnicity
• Lifestyle factors: Sedentary lifestyle, immobility, low body weight (<125 lbs)
• Nutritional factors: Low calcium intake throughout life, vitamin D deficiency, malnutrition
• Reproductive factors: Weight loss (>10% of weight at age 25), nulliparity (never having given birth)
• Medical conditions: Gastrointestinal disorders, malabsorption syndrome, hypoparathyroidism
• Medication use: Long-term corticosteroid use, certain other medications

Key Characteristics

• Drug class: Human monoclonal antibody, RANKL inhibitor
• Formulation: Injectable solution (60 mg/mL in a 1 mL prefilled syringe or vial)
• Administration: Subcutaneous injection given once every 6 months
• FDA approval: Granted for high-risk osteoporosis patients
• Molecular weight: Approximately 147 kDa

1. Postmenopausal Women with Osteoporosis

At high risk for fracture, including those who:

• Have a history of osteoporotic fracture
• Have multiple risk factors for fracture
• Have failed or are intolerant to other osteoporosis therapies

2. Men with Osteoporosis

At high risk for fracture

3. Glucocorticoid-Induced Osteoporosis

In men and women taking corticosteroid medications (like prednisone) for at least 6 months and at high risk for fracture

4. Bone Loss in Men Receiving Androgen Deprivation Therapy

For non-metastatic prostate cancer

5. Bone Loss in Women Receiving Aromatase Inhibitor Therapy

For non-metastatic breast cancer

Participant Characteristics

• Mean age: 72.3 years
• Baseline T-scores: Lumbar spine -2.8, total hip -1.9, femoral neck -2.2
• 24% had a baseline vertebral fracture

Primary Results - Risk Reductions

Bone Mineral Density Improvements

• Lumbar spine: 9.2% increase
• Total hip: 6.0% increase

Bone Turnover Markers

• 86% decrease in bone resorption markers at 1 month
• 72% sustained decrease at 36 months

Why Prolia Achieves Greater BMD Increases

1. More Potent Antiresorptive Effect:

While bisphosphonates must bind to bone mineral to be effective, Prolia is a monoclonal antibody that directly targets RANKL—the key protein that stimulates bone breakdown. By blocking RANKL, Prolia more potently inhibits the survival and differentiation of osteoclasts (bone-resorbing cells), resulting in more significant bone density improvements.

2. Continuous Improvement Over Time:

Unlike bisphosphonates, which often reach a plateau in BMD gains after a few years, long-term data show that Prolia continues to increase BMD at the lumbar spine and hip for up to 10 years of treatment. Studies have confirmed that when patients transition from bisphosphonates to Prolia, they experience significant further increases in BMD that were not achievable by continuing bisphosphonate therapy alone.

Administration Details

• Route: Subcutaneous injection (under the skin)
• Injection Sites: Upper arm, upper thigh, or abdomen
• Frequency: Once every 6 months (every 26 weeks)
• Who Administers: A healthcare professional in a hospital, clinic, or doctor's office

Immediate Effects (Within Days)

• Bone resorption markers decrease by 85% within 3 days
• This demonstrates the drug is actively working

Short-term Effects (1-3 Months)

• Maximum reduction in bone breakdown
• Many patients show undetectable bone resorption markers
• Bone begins to strengthen

Long-term Effects (12-36 Months)

• Progressive increases in bone mineral density
• Significant fracture risk reduction becomes evident
• Continued strengthening of both cortical and trabecular bone

10-Year Data

Studies show continued efficacy and safety with sustained BMD improvements over a decade of treatment.

2. Osteonecrosis of the Jaw (ONJ)

What it is: Exposed bone in the jaw that fails to heal for 6-8 weeks

Risk factors:

• Prior bisphosphonate therapy
• Dental surgery or tooth extraction
• Poor oral hygiene
• Cancer (breast, prostate, myeloma)
• Smoking

Prevention:

• Complete dental exam and treatments BEFORE starting Prolia
• Maintain excellent oral hygiene
• Regular dental check-ups
• Inform dentist you're taking Prolia
• Avoid invasive dental procedures if possible

3. Atypical Femoral Fractures

• Unusual fractures of the thigh bone
• May occur with minimal or no trauma
• Warning signs: Dull, aching pain in hip, groin, or thigh weeks to months before fracture
• More common with long-term use

4. Serious Infections

Increased risk of infections, including:

• Cellulitis (skin infection)
• Erysipelas
• Endocarditis (heart infection)
• Serious skin infections

Higher risk in:

• Patients taking immunosuppressant medications
• Those with compromised immune systems

5. Multiple Vertebral Fractures Upon Discontinuation

• Risk of rapid bone loss and multiple spinal fractures after stopping Prolia
• Effects wear off very quickly (within months)
• Critical: Do not stop Prolia without a transition plan to another osteoporosis medication

Hypocalcemia Prevention

1. Pre-treatment assessment:
   • Blood calcium level check
   • Kidney function testing
   • Vitamin D level assessment
2. Supplementation:
   • Calcium 1,000 mg daily (through diet and/or supplements)
   • Vitamin D at least 400 IU daily (some patients may need 800-1,000 IU)
   • Take consistently throughout treatment
3. Monitoring:
   • Regular blood tests before each injection
   • Additional monitoring 2 weeks post-injection if high-risk
   • Report symptoms immediately

Infection Prevention

1. Practice good hygiene
2. Avoid sick individuals when possible
3. Report any signs of infection promptly:
   • Fever
   • Chills
   • Skin redness, warmth, or swelling
   • Pain or discomfort

Dental Health Maintenance

Before starting Prolia:

• Complete dental examination
• Address any dental issues
• Ensure proper denture fit

During treatment:

• Brush teeth at least twice daily
• Floss daily
• Regular dental cleanings (inform dentist about Prolia)
• Avoid elective invasive dental procedures
• Report any jaw pain, swelling, or loose teeth immediately